Table 2.

Characteristics of Study Infants (<1251 g at Birth and Survived Beyond 28 Days of Age)

 Groups
(Total = 177)
NL
(n = 35)
RDS
(n = 54)
BPD
(n = 61)
Atypical CLD
(n =  27)
BPD Versus
Atypical CLDP
Gestation in weeks* 30 (±1.8)29 (±1.6)26 (±1.6)27 (±1.3)0.038
Birth weight* 1047 g (±137)1096 g (±135)854 g (±173)922 g (±152)0.025
Male/female18/1724/3026/3513/14NS
SGA§ 15 (43%)14 (26%)6 (10%)1 (4%)NS
Prenatal corticosteroids§ 9/18 (50%)9/30 (30%)18/47 (38%)10/22 (45%)NS
Therapeutic surfactant§ 017 (31%)36 (60%)8 (40%) NS
Length of oxygen therapy (days) 1 (0, 16)3 (0, 32)48 (19, 180)30 (11, 163)0.0001
Length of oxygen therapy beyond
 36 weeks' CGA (days) −42 (−63, −14)−45 (−63, −20)−21 (−55, 117)−35 (−60, 104)0.0003
Length of IPPV (days) 0 (0, 24)6.5 (0, 67)42 (4, 154)31 (2, 127)0.0027
Dexamethasone therapy§ 0029 (47%)9 (33%)NS
Length of hospitalization beyond
 36 weeks' CGA among survivors (days) 6.5 (−23, 56)7 (−17.5, 77)25 (−48, 162)22 (−56, 218)NS
Infants on oxygen at or beyond
 36 weeks' CGA§ 0017 (28%)3 (11%)NS
Expired§ 008 (13%)2 (7%) NS
  • Abbreviations: SGA, small for gestational age; IPPV, intermittent positive pressure ventilation.

  • * Mean  (± SD).

  • Median (min, max).

  • Comparing classic BPD (61) versus CLDpRDS (20) infants, because by definition DCLD infants did not have RDS and, hence, did not receive therapeutic surfactant.

  • § Number of patients (%); NS, not statistically significant (P > 0.05).